Pharma BD Deal Intelligence
Gilead Sciences Inc. / Goldfinch Bio Inc.
2019 · Licensing/Option · $240M · Complete
Announcement Sentiment
86
Strongly positive
Outcome Score
26
Did not work — the deal failed to deliver.
Gilead partnered with Goldfinch Bio to develop kidney disease therapies, paying $55M upfront plus $54M in research funding with up to $2B in milestones.
Key facts
Announced May 08, 2019 Closed May 08, 2019 Deal value $240M Deal type Licensing/Option Therapeutic area Nephrology Indications Kidney diseases Key assets Kidney disease candidates Mechanism Undisclosed kidney disease targets
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About